Biocompatibility of poly(D,L-lactide-co-glycolide) nanoparticles conjugated with alendronate.
about
Toxicity of nanomaterialsSynthesis and biological evaluation of a new polymeric conjugate and nanocarrier with osteotropic propertiesControlled delivery of zoledronate improved bone formation locally in vivoAction of Nanoparticles on Platelet Activation and Plasmatic CoagulationTargeting polymer therapeutics to bone.Double-tailed acyl glycoside niosomal nanocarrier for enhanced oral bioavailability of Cefixime.Sugar-based novel niosomal nanocarrier system for enhanced oral bioavailability of levofloxacin.Hydrophilically modified self-assembling α-tocopherol derivative as niosomal nanocarrier for improving clarithromycin oral bioavailability.Transplantable delivery systems for in situ controlled release of bisphosphonate in orthopedic therapy.Polymeric materials for theranostic applications.Bisphosphonates: therapeutics potential and recent advances in drug delivery.Development of a biocompatible creatinine-based niosomal delivery system for enhanced oral bioavailability of clarithromycin.Degradation behavior and biosafety studies of the mPEG-PLGA-PLL copolymer.Plant extracts: from encapsulation to application.The effects of nanomaterials on blood coagulation in hemostasis and thrombosis.A multimodal magnetic resonance imaging nanoplatform for cancer theranostics.Effects of 15d-PGJ₂-loaded poly(D,L-lactide-co-glycolide) nanocapsules on inflammation.Engineering nanocages with polyglutamate domains for coupling to hydroxyapatite biomaterials and allograft bone.Platelet compatibility of PLGA, chitosan and PLGA-chitosan nanoparticles.On-chip synthesis of fine-tuned bone-seeking hybrid nanoparticles.Synthesis, characterization and osteoconductivity properties of bone fillers based on alendronate-loaded poly(ε-caprolactone)/hydroxyapatite microspheres.HGF and IGF-1 promote protective effects of allogeneic BMSC transplantation in rabbit model of acute myocardial infarction.PLGA-linked alendronate enhances bone repair in diaphysis defect model.Influence of PEG chain on the complement activation suppression and longevity in vivo prolongation of the PCL biomedical nanoparticles.Creatinine-based non-phospholipid vesicular carrier for improved oral bioavailability of Azithromycin.Bisphosphonate conjugation for bone specific drug targeting.Hemolytic and cellular toxicology of a sulfanilamide-based nonionic surfactant: a niosomal carrier for hydrophobic drugs
P2860
Q28383168-5E16EFED-6985-4AB7-BEEE-C67309599CDEQ28386509-F15E727D-7704-480C-BAE9-E24B68877D88Q28540762-0D9A4705-CB3B-41BC-B335-43F0597B1633Q33600393-D44920AE-326E-460B-BAFC-55D297D9969DQ35951743-5A814F33-110B-4CBD-8219-206555A79FB5Q36185274-85F97B7D-21CC-4098-AE0B-BF47C1A8DCFDQ36203995-FC7211F0-AA94-4F1A-984F-8F31390CF51CQ36379940-FED99270-D746-4489-90EC-B6CBE36FCFB0Q37822757-A9CD9880-F308-447D-BC13-6166B24BEF5DQ38114360-1B2E6D98-BFB4-46B8-BE86-1B38DFF31FA8Q38176927-CB3EA53F-7405-4955-B51E-8C95F96AB2C2Q38767228-50597F34-B89A-4D22-ABC2-D87BD3598995Q38779247-C3A52A89-8BE1-4F95-AE5E-1E1B62755270Q38823966-A02176E4-E468-4C11-A718-8FFB7EB5F860Q39081782-B24D61B7-7369-4753-BB3B-0A381939BDC5Q39575498-252B3738-8465-494E-81D8-821EAE09CC07Q41856124-2B03AFCA-3C44-42C6-AEA2-1B1965EDAC80Q41875872-3816E1AE-E3A5-4F85-9389-888692BC6E4DQ44765785-18F7A65F-46B6-4C4E-B306-0632BAA75D23Q46212862-A8586FAE-A952-4310-AC0D-086DA7AD3D92Q50643735-6A346D6C-CB3F-4D55-B719-CBEBD4A27F0FQ50924469-099AA631-8845-452F-8F83-3D011C44880CQ51722998-D4506654-E031-4637-A411-FD3019D493DDQ53383193-AB9588C4-B3A9-47B4-BB64-BD517875C48CQ53528770-78CE4328-6F81-45EA-9502-D1D5E3D6E17CQ55515922-8A6C350F-83DC-4911-B918-C1E39ACB6CC7Q57496984-2AFDEAC3-082F-4045-808E-24227A6B2C73
P2860
Biocompatibility of poly(D,L-lactide-co-glycolide) nanoparticles conjugated with alendronate.
description
2008 nî lūn-bûn
@nan
2008 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Biocompatibility of poly(D,L-l ...... s conjugated with alendronate.
@ast
Biocompatibility of poly(D,L-l ...... s conjugated with alendronate.
@en
Biocompatibility of poly(D,L-l ...... s conjugated with alendronate.
@nl
type
label
Biocompatibility of poly(D,L-l ...... s conjugated with alendronate.
@ast
Biocompatibility of poly(D,L-l ...... s conjugated with alendronate.
@en
Biocompatibility of poly(D,L-l ...... s conjugated with alendronate.
@nl
prefLabel
Biocompatibility of poly(D,L-l ...... s conjugated with alendronate.
@ast
Biocompatibility of poly(D,L-l ...... s conjugated with alendronate.
@en
Biocompatibility of poly(D,L-l ...... s conjugated with alendronate.
@nl
P2093
P50
P1433
P1476
Biocompatibility of poly(D,L-l ...... s conjugated with alendronate.
@en
P2093
Caterina Fotia
Dorotea Micieli
Elisabetta Cenni
Manuela Salerno
Maria G Sarpietro
P304
P356
10.1016/J.BIOMATERIALS.2007.12.022
P577
2008-01-11T00:00:00Z